LeonaBio targets Phase 3 ELAINE-3 enrollment completion in Q4 2026, topline data seen in H2 2027
LONA•Phase 3 timeline remains on track
LeonaBio outlined plans to spotlight lasofoxifene at DAVA Oncology’s breast cancer summit on Aug. 18-22, 2026.
No new trial results were disclosed; Phase 3 ELAINE-3 enrollment remains on track to finish in Q4 2026.
Topline ELAINE-3 data are expected in H2 2027, setting up a major catalyst for the metastatic breast cancer program.
Trial focus and potential treatment role
The study tests lasofoxifene with abemaciclib in ER-positive, HER2-negative, ESR1-mutated metastatic breast cancer.
Management positioned the regimen as a potential new treatment option if the pivotal trial delivers supportive efficacy and safety outcomes.
